On September 25, 2025, Organogenesis Holdings Inc. reported that their second Phase 3 trial of ReNu for knee osteoarthritis involved 594 patients but did not achieve statistical significance for its primary endpoint, showing baseline pain reduction of -6.9 compared to -6.0 in the first trial. The company plans to discuss the BLA submission pathway with the FDA by the end of October 2025.